Ambee Pharmaceuticals PLC announcements
253 Dhaka Stock Exchange announcements for Ambee Pharmaceuticals PLC (AMBEEPHA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2021 (20).
- Resumption after record date
Trading of the shares of the Company will resume on 06.12.2021 after record date.
- Suspension for Record date
Trading of the shares of the Company will remain suspended on record date i.e., 05.12.2021.
- Spot News
Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle from 01.12.2021 to 02.12.2021. Trading of the shares of the Company will remain suspended on record date i.e., 05.12.2021.
- Q1 Financials
(Q1 Un-audited): EPS was Tk. 0.10 for July-September 2021 as against Tk. 0.15 for July-September 2020; NOCFPS was Tk. 8.37 for July-September 2021 as against Tk. 0.68 for July-September 2020. NAV per share was Tk. 18.79 as on September 30, 2021 and Tk. 18.68 as on June 30, 2021.
- The auditor of the Ambee Pharmaceuticals Ltd. has given the \"Qualified Opinion\" paragraphs in the Auditor\'s Report fo
The auditor of the Ambee Pharmaceuticals Ltd. has given the \"Qualified Opinion\" paragraphs in the Auditor\'s Report for the year ended on 30 June, 2021. Basis for Qualified Opinion: 1. As disclosed in note # 20.00, the company has shown Tk. 9,948,826 as liabilities for WPF & WWF which includes prior year\'s amount of Tk. \r\n9,127,363 that has not been paid by the company to the Fund. As per section 234 (b) of Labour Act, 2006 the company should pay the amount to the WPF & WWF not (cont.1)
- (Continuation news of AMBEEPHA): later than nine months from the end of the respective year. 2. As disclosed in note # 1
(Continuation news of AMBEEPHA): later than nine months from the end of the respective year. 2. As disclosed in note # 18.02, the company has shown Tk. 1,916,358 as Payable to Provident Fund. The amount is carried forward from earlier years. As no financial statement of Provident Fund was made available to us, so we are not sure whether there is any forfeited fund returned to company\'s account from the contributory provident fund as per notification no. 179/FRC/FRM/2020/2, dated (cont.2)
The first part of this announcement is missing from the archive. - (Continuation news of AMBEEPHA): July 07, 2020 of the Financial Reporting Council (FRC). 3. As disclosed in note # 21.00
(Continuation news of AMBEEPHA): July 07, 2020 of the Financial Reporting Council (FRC). 3. As disclosed in note # 21.00, the company has shown Tk. 3,856,352 as Unclaimed Dividend. As the company has no designated bank account for dividend, so we are not sure whether the dividend was paid to the shareholders within the stipulated time as per section 28(1) of Dhaka Stock Exchange (Listing) (cont.3)
The first part of this announcement is missing from the archive. - The auditor of the Ambee Pharmaceuticals Ltd.has given the \"Emphasis of matter\" paragraphs in the Auditor\'s Report fo
The auditor of the Ambee Pharmaceuticals Ltd.has given the \"Emphasis of matter\" paragraphs in the Auditor\'s Report for the year ended on 30 June, 2021. Emphasis of Matter: In forming our opinion on the Financial Statements, which is not modified, we considered the following matter and the fact that as per note # 10.01, the company reported an amount of Tk. 12,796,385 as cash in hand. (cont.1)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 22, 2021 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2021.
- Emphasis of Matter
(Continuation news of AMBEEPHA): Physical counting of cash in hand at Head Office for Tk. 13,548 and Factory for Tk. 4,357 only was done by the management at the year-end. (end)
The first part of this announcement is missing from the archive. - Qualified Opinion
(Continuation news of AMBEEPHA): Regulations, 2015 and in compliance with clause 3 (vii) of the Bangladesh Securities and Exchange Commission (BSEC) Directive No. BSEC/CMRRCD/2021-386/03, dated 14 January 2021. (end)
The first part of this announcement is missing from the archive. - Dividend Declaration
The Board of Directors has recommended No dividend for the year ended on June 30, 2021. Date of AGM: 28.12.2021, Time: 11:00 AM, Venue: digital platform. Record date: 05.12.2021. The Company has also reported EPS of Tk. (5.42), NAV per share of Tk. 18.68 and NOCFPS of Tk. (2.77) for the year ended on June 30, 2021 as against Tk. 1.52, Tk. 24.10 and Tk. (4.99) respectively for the same period of the previous year.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (14.11.2021) following its corporate declaration.
- Dividend Declaration (Additional Information)
The Company has further informed that NOCFPS of Tk. (2.27) instead of Tk. (2.77) for the year ended on June 30, 2021. All other information will remain unchanged.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 11, 2021 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2021.
- Dividend Disbursement
The Company has informed that it has disbursed the cash dividend for the year ended on June 30, 2020 to the respective shareholders.
- Query Response
In response to a DSE query dated September 12, 2021, the Company has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike and increase in volume of shares.
- Q1 Financials
(Q1 Un-audited): EPS was Tk. 0.15 for July-September 2020 as against Tk. 0.75 for July-September 2019; NOCFPS was Tk. 0.68 for July-September 2020 as against Tk. 0.44 for July-September 2019. NAV per share was Tk. 24.25 as on September 30, 2020 and Tk. 24.10 as on June 30, 2020.
- Q2 Financials
(Q2 Un-audited): EPS was Tk. 0.20 for October-December, 2020 as against Tk. 0.88 for October-December, 2019; EPS was Tk. 0.35 for July-December, 2020 as against Tk. 1.63 for July-December, 2019. NOCFPS was Tk. 0.54 for July-December, 2020 as against Tk. 0.07 for July-December, 2019. NAV per share was Tk. 22.95 as on December 31, 2020 and Tk. 24.10 as on June 30, 2020.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 0.30 for January-March 2021 as against Tk. 0.75 for January-March 2020; EPS was Tk. 0.65 for July 2020-March 2021 as against Tk. 2.38 for July 2019-March 2020. NOCFPS was Tk. 3.89 for July 2020-March 2021 as against Tk. 0.09 for July 2019-March 2020. NAV per share was Tk. 23.25 as on March 31, 2021 and Tk. 24.10 as on June 30, 2020.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.